Search results for "slas europe 2018"

Watch this on demand webinar to learn more about mRNA vaccine development and manufacturing processes

Access Anti-SARS-CoV-2 is an easy-to-use 10-minute test on a portable device that provides highly accurate results on total Ig antibodies

The study is the first global, randomized, double-blind, placebo-controlled phase III trial investigating Actemra/RoActemra in this setting

Experts discuss the evolving landscape of clinical mass spectrometry, the impact of automation, challenges in integration, and what the future holds

In this guest editorial from the Clinical and Laboratory Standards Institute (CLSI), explore FDA clearance pathways and how CLSI standards can help expedite regulatory approval

Eurofins’ Ryan Francis discusses the development of new ambient mass spectrometry instrumentation to accelerate drug testing services

Malvern Instruments has released two new articles detailing its work in engineering and emulsification

Revvity Signals Signals™ Notebook is the next-generation cloud-native electronic lab notebook (ELN) and scientific collaboration platform for today’s scientists. It is the only future-proof ELN that covers a comprehensive set of scientific use cases, spanning biology, chemistry, formulations, analysis, and more in an intuitive, searchable, scalable and secure platform. 

Gilson Connect and SciNote aim to overcome the lack of reproducibility across scientific articles

Stages used for controlled beamline analysis experiments to support research in life, physical, and environmental sciences

Origin: from Olea europaeaFormula: C17H24O11M: 404.38 g/molCAS-No.: 60539-23-3HS-No.: 29420000Storage: 2-8°CSpecification: Assay: min. 98 %

Origin: from Olea europaeaFormula: C25H32O13M: 540.52 g/molCAS-No.: 32619-42-4HS-No.: 29420000Storage: 2-8°CSpecification: Assay: min. 98 %

Origin: from Olea europaeaFormula: C25H32O13M: 540.52 g/molCAS-No.: 32619-42-4HS-No.: 29420000Storage: 2-8°CSpecification: Assay: min. 90 %

Women with a rare type of ovarian cancer could benefit from a drug that quadruples the likelihood of response compared with standard therapies